Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

• Main Authors: Christelle Remy-Ziller (Author), Christine Thioudellet (Author), Julie Hortelano (Author), Murielle Gantzer (Author), Virginie Nourtier (Author), Marie-Christine Claudepierre (Author), Benoit Sansas (Author), Xavier Préville (Author), Kaïdre Bendjama (Author), Eric Quemeneur (Author), Karola Rittner (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. To support its development, preclinical experiments were performed with either TG4...